Skip to content

Pfizer’s RSV Vaccine Wins US Panel’s Backing for Safety in Older People

  • Panel members focused on data concerns before positive vote
  • Postmarketing studies will be crucial, panel members say
Pfizer headquarters in New York.
Pfizer headquarters in New York.Photographer: Stephanie Keith/Bloomberg
Updated on

Pfizer Inc.’s vaccine for respiratory syncytial virus received backing from a panel of US advisers for use in people 60 and older, pushing the company to the forefront once again for immunization against a dangerous respiratory illness. 

Members of the panel that advises the Food and Drug Administration voted 7-4 with one abstention to recommend the vaccine as both safe and effective in preventing RSV. Still, several who endorsed the shots also raised concerns about the lack of data on hospitalizations and the highest-risk patients, as well as two incidents of a rare disorder among those who were vaccinated.